In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...

First, because of periodic surveillance of patients with a hereditary predisposition ... have become an important clinical entity for which pheochromocytoma must be considered, regardless of ...

The role of chromogranin A in the assessment of surgical cure of pheochromocytoma was also investigated. The authors observed 21 consecutive patients who had pheochromocytomas at initial ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Pheochromocytoma. Surgery ... Avoid abruptly discontinuing Toprol-XL in patients treated only for hypertension. When discontinuing chronically administered Toprol-XL especially in patients ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.